{"schema_version":"1.0","type":"article","title":"Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King?","url":"https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king-en.md","lang":"en","date":"2026-08-18","publish_at":"2026-08-18T08:00:00+08:00","updated_at":"2026-08-18","category":"商業分析系列","topic":"商業分析系列","tags":["Eli Lilly","Eli Lilly","Tirzepatide","Mounjaro","Zepbound","GLP-1","Retatrutide","Orforglipron","Caliway"],"summary":"Tirzepatide has allowed Eli Lilly to dominate both diabetes and obesity, but revenue concentration, pricing pressure and the next product relay are the investment questions that matter now.","key_points":[],"facts":[],"sections":["01 | One molecule, two large markets","02 | Lilly is leading, but the price war has already started","03 | Oral and triple agonist programs are Lilly's own relay","04 | Sleep, CAR-T and vaccines: Lilly is buying a second mountain","05 | The real moat is moving science into factories","06 | Taiwan read-through: Caliway is a research case, not a Lilly concept stock","References","Disclaimer"],"references":[{"title":"[Eli Lilly 2026 Q2 Form 10-Q]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm"},{"title":"[Eli Lilly 2026 Q2 sales and earnings press release]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm"},{"title":"[FDA approval announcement for Foundayo]","source":"","date":"","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program"},{"title":"[Foundayo prescribing information]","source":"","date":"","url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf"},{"title":"[NEJM SURMOUNT-5 tirzepatide versus semaglutide]","source":"","date":"","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2416394"},{"title":"[Lilly Zepbound versus Wegovy SURMOUNT-5 release]","source":"","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy"},{"title":"[Lilly retatrutide TRIUMPH-1 Phase 3 topline release]","source":"","date":"","url":"https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html"},{"title":"[Novo Nordisk 2026 Q2 results]","source":"","date":"","url":"https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916590"},{"title":"[Lilly acquisition and infectious-disease portfolio releases]","source":"","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-announces-three-acquisitions-build-infectious-disease"},{"title":"[Lilly Indiana manufacturing investment]","source":"","date":"","url":"https://investor.lilly.com/news-releases/news-release-details/lilly-commits-additional-45-billion-across-indiana-manufacturing"},{"title":"[Caliway CBL-514 and tirzepatide combination trial announcement]","source":"","date":"","url":"https://www.caliwaybiopharma.com/news-detail/Caliway-Submits-IND-for-Cbl-514-Combination-Therapy-Phase-2/"},{"title":"Verification cutoff: August 18, 2026.","source":"","date":"","url":""}],"images":[{"alt":"Figure 1 | Tirzepatide now anchors both diabetes and obesity revenue, making concentration the central strategic question","url":"https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king-en/figure-01.png"},{"alt":"Figure 2 | Lilly is trying to turn tirzepatide cash flow into a product relay spanning oral GLP-1 and a next-generation triple agonist","url":"https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king-en/figure-02.png"},{"alt":"Figure 3 | Lilly is using tirzepatide cash flow to buy options in sleep, in vivo CAR-T, vaccines and psychiatric disease","url":"https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king-en/figure-03.png"},{"alt":"Figure 4 | Caliway's CBL-514 program is a research read-through to the GLP-1 era, not evidence of a Lilly supply-chain relationship","url":"https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king-en/cover-editorial.jpg","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-18）。Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King?。https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh":"2026-08-18-eli-lilly-tirzepatide-next-drug-king.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}